This is the wild story of how a Cold War bioweapon became Botox — and how Allergan turned a sleepy ophthalmology drug into an enduring aesthetic franchise.

Why a profitable pharma company buying back stock is usually telling on itself

How two industries with nothing in common converged on the same business model

BCG, bladder cancer, and drug repurposing from the weirdest of places

Some thoughts on Peter Thiel's view of the beta-amyloid hypothesis as a lens for understanding the messy, slow cost of figuring out how to make drugs for complex diseases.

Amylin pioneered the incretin class & staked their future on obesity 20+ yrs ago, yet sold for only $7B in 2012 - a pittance for the foundation of what is now a trillion dollar market. What happened?

How Axiom Bio is trying to fix drug safety testing.

Or: How Modern Oncology and Employer Insurance Would Have Ruined the Entire Premise

For centuries it was a poison. Then colchicine rewrote treatment for gout, heart disease, and later, the debate over drug exclusivity.

...Did everyone just panic-buy an FGF21?

In 2014, Amgen sued Sanofi and Regeneron to claim ownership of an entire class of cholesterol drugs. Nine years later, the Supreme Court ruled against them - but they won where it mattered most.

A review of Yossi Goldstein's "Eli Hurvitz and the Creation of Teva Pharmaceuticals"

How a Swiss pharma giant built the last great corporate research skunkworks - and why that model may never work again.

An admittedly partial–but deeply troubling–case against America's most brazen medical grift, involving Chinese knockoffs, subscription traps, and prescription gas station sex pills.

A response to Francis Fukuyama's case against longevity research

What it's like living as someone working in biotech in San Francisco.

One regulatory stroke could save more American lives than a decade of health campaigns. You have the pen.

Populism, policy, and poker: Makary’s volatile hand at the FDA

On the quiet horror of healthspan science and its desperate decorum

A not-so-casual reminder that your molecule isn’t a molecule—it’s a movie pitch.

Their moat is made of dead animals – but now the rats are leaving. Can Charles River take the hit?

(Kind of, eventually, maybe)

Legacy, lethargy, and the urgent case for reinvention